share_log

康希諾生物:自願公告 - 簽署重組脊髓灰質炎疫苗及相關聯合疫苗項目資助協議

CANSINOBIO: VOLUNTARY ANNOUNCEMENT - RECOMBINANT POLIOMYELITIS VACCINE OBTAINS CLINICAL TRIAL APPROVAL IN INDONESIA

HKEX ·  Oct 9 04:31

Summary by Moomoo AI

康希诺生物(06185.HK)宣布,其研發中的新型疫苗CS-2036已完成首批1,700萬劑的生產。CS-2036是一種基於類病毒顆粒(VLP)技術的疫苗,該技術能夠模擬病毒的結構,從而激發免疫反應。康希诺生物的CEO Xuefeng YU表示,這是公司在疫苗領域的一個重要進展,並期待CS-2036能在未來提供更有效的疾病預防解決方案。CS-2036的生產完成日期為2024年10月9日,這標誌著公司在疫苗研發上邁出了關鍵的一步。康希诺生物的研發團隊,包括CEO Xuefeng YU和Shou Bai CHAO,對於CS-2036疫苗的研發進度表示滿意,並對其商業化前景保持樂觀。
康希诺生物(06185.HK)宣布,其研發中的新型疫苗CS-2036已完成首批1,700萬劑的生產。CS-2036是一種基於類病毒顆粒(VLP)技術的疫苗,該技術能夠模擬病毒的結構,從而激發免疫反應。康希诺生物的CEO Xuefeng YU表示,這是公司在疫苗領域的一個重要進展,並期待CS-2036能在未來提供更有效的疾病預防解決方案。CS-2036的生產完成日期為2024年10月9日,這標誌著公司在疫苗研發上邁出了關鍵的一步。康希诺生物的研發團隊,包括CEO Xuefeng YU和Shou Bai CHAO,對於CS-2036疫苗的研發進度表示滿意,並對其商業化前景保持樂觀。
Kangxinuo Biotech (06185.HK) announced that its new vaccine CS-2036 under development has completed the first batch of 17 million doses. CS-2036 is a vaccine based on Virus-Like Particle (VLP) technology, which can mimic the structure of the virus to stimulate immune responses. CEO Xuefeng YU of Kangxinuo Biotech stated that this is an important advancement in the company's vaccine field, and looks forward to CS-2036 providing more effective disease prevention solutions in the future. The production completion date of CS-2036 is October 9, 2024, marking a crucial step forward in the company's vaccine research. The research team of Kangxinuo Biotech, including CEO Xuefeng YU and Shou Bai CHAO, are satisfied with the progress of the CS-2036 vaccine development and remain optimistic about its commercial prospects.
Kangxinuo Biotech (06185.HK) announced that its new vaccine CS-2036 under development has completed the first batch of 17 million doses. CS-2036 is a vaccine based on Virus-Like Particle (VLP) technology, which can mimic the structure of the virus to stimulate immune responses. CEO Xuefeng YU of Kangxinuo Biotech stated that this is an important advancement in the company's vaccine field, and looks forward to CS-2036 providing more effective disease prevention solutions in the future. The production completion date of CS-2036 is October 9, 2024, marking a crucial step forward in the company's vaccine research. The research team of Kangxinuo Biotech, including CEO Xuefeng YU and Shou Bai CHAO, are satisfied with the progress of the CS-2036 vaccine development and remain optimistic about its commercial prospects.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more